Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study-Reference-Cited by-同舟云学术

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study

Published:2018-06-29 Issue:13 Volume:2 Page:1532-1540
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Flasinski Marius¹,Scheibke Kira¹,Zimmermann Martin¹,Creutzig Ursula¹,Reinhardt Katarina²,Verwer Femke³,de Haas Valerie³,van der Velden Vincent H. J.⁴,von Neuhoff Christine⁵,Zwaan C. Michel³⁶,Reinhardt Dirk²,Klusmann Jan-Henning⁷^ORCID

Affiliation:

1. Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany;

2. Pediatric Hematology and Oncology, Pediatrics III, University Hospital Essen, Essen, Germany;

3. Dutch Childhood Oncology Group, Den Haag, The Netherlands;

4. Department of Immunology, Laboratory Medical Immunology, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands;

5. Department of Pediatric Psychiatry and Psychosomatic Medicine, Landschaftsverband-Rheinland Clinic, University Duisburg/Essen, Essen, Germany;

6. Department of Pediatric Oncology/Hematology, Erasmus Medical Center/Sophia Children's Hospital, Rotterdam, The Netherlands; and

7. Department of Pediatric Hematology and Oncology, Martin Luther University Halle-Wittenberg, Halle, Germany

Abstract

Key Points Low-dose cytarabine treatment reduced mortality in symptomatic TMD patients compared with the historical control. An MRD monitoring–based low-dose cytarabine treatment does not prevent progression from preleukemic TMD to ML-DS.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/2/13/1532/881442/advances018945.pdf

Reference23 articles.

1. Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome;Pine;Blood,2007

2. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts;Langebrake;Klin Padiatr,2005

3. GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia;Roberts;Blood,2013

4. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children’s Oncology Group Study A2971;Gamis;Blood,2011

5. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome;Klusmann;Blood,2008

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytokine profiling in 128 patients with transient abnormal myelopoiesis: a report from the JPLSG TAM-10 trial;Blood Advances;2024-06-13

2. Down syndrome-associated leukaemias: current evidence and challenges;Therapeutic Advances in Hematology;2024-01

3. Myeloid Proliferation Associated with Down Syndrome (ML-DS, TAM);Pediatric Oncology;2024

4. Too many white cells—TAM, JMML, or something else?;Hematology;2023-12-08

5. Death of children with Down syndrome by gestational age and cause;Pediatric Research;2023-10-28